Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma

19 Jul 2024

Abstract excerpt

Targeted immunotherapy combinations, including the anti-CD38 monoclonal antibody (MoAb) daratumumab, have shown promising results in patients with relapsed/refractory multiple myeloma (RRMM), leading to a considerable increase in progression-free survival. However, a large fraction of patients inevitably relapse. To understand this, we investigated 32 relapsed MM patients treated with daratumumab, lenalidomide,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Chronic Lymphocytic Leukemia Research
Share to Multiple Myeloma Research and Treatments

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39030183
DOI: 10.1038/s41408-024-01096-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 21 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myelomaPMID 39030183Read ↗

Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myelomaSemantic proximity Read ↗

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myelomaSemantic proximity Read ↗

The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myelomaSemantic proximity Read ↗

Plasma cell identity escape drives resistance to anti-BCMA T-cell–redirecting therapy in multiple myelomaSemantic proximity Read ↗

CD38 biallelic loss is a recurrent mechanism of resistance to anti-CD38 antibodies in multiple myelomaSemantic proximity Read ↗

Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myelomaSemantic proximity Read ↗

Longitudinal multi-omic profiling uncovers immune escape and predictors of response in multiple myelomaSemantic proximity Read ↗

Multiple Myeloma and Precursor Plasma Cell Disorders: From Emerging Driver Mutations to Current and Future Therapeutic StrategiesSemantic proximity Read ↗

Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myelomaSemantic proximity Read ↗

Multiple Myeloma Insights from Single-Cell Analysis: Clonal Evolution, the Microenvironment, Therapy Evasion, and Clinical ImplicationsSemantic proximity Read ↗

Utilizing Genomics to Identify Novel Immunotherapeutic Targets in Multiple Myeloma High-Risk SubgroupsSemantic proximity Read ↗

DNA damage repair (DDR) related prognostic risk model in multiple myeloma based on single-cell and bulk sequencing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.